Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
BIORA THERAPEUTICS, INC. (PROG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/06/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/17/2023 |
4
| NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 36,183 shares
@ $3.14, valued at
$113.6k
Granted 210,175 shares
@ $0 |
|
| 08/17/2023 |
4
| dEsparbes Eric (CFO) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 40,022 shares
@ $3.14, valued at
$125.7k
Granted 219,650 shares
@ $0 |
|
| 08/17/2023 |
4
| MOHANTY ADITYA P. (CEO) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 117,881 shares
@ $3.14, valued at
$370.1k
Granted 559,450 shares
@ $0 |
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Investor presentation, Quarterly results |
| 07/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/16/2023 |
4
| Kotzin Brian L. (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Granted 12,500 shares
@ $0
Granted 12,500 options to buy
@ $4.7, valued at
$58.8k
|
|
| 06/16/2023 |
4
| Powell Lynne (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Granted 12,500 shares
@ $0
Granted 12,500 options to buy
@ $4.7, valued at
$58.8k
|
|
| 06/16/2023 |
4
| Alter Jeffrey D. (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Granted 12,500 shares
@ $0
Granted 12,500 options to buy
@ $4.7, valued at
$58.8k
|
|
| 06/16/2023 |
4
| Howe Jill Ann (Director) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Granted 12,500 shares
@ $0
Granted 12,500 options to buy
@ $4.7, valued at
$58.8k
|
|
| 06/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/13/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/08/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/17/2023 |
4
| dEsparbes Eric (CFO) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 2,807 shares
@ $3.35, valued at
$9.4k
|
|
| 05/17/2023 |
4
| NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 2,368 shares
@ $3.35, valued at
$7.9k
|
|
| 05/17/2023 |
4
| MOHANTY ADITYA P. (CEO) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Paid exercise price by delivering 11,249 shares
@ $3.35, valued at
$37.7k
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
4
| NEUMANN CLARKE (See Remarks) has filed a Form 4 on BIORA THERAPEUTICS, INC.|
Txns:
| Granted 57,950 shares
@ $0
Granted 21,684 shares
@ $0
Paid exercise price by delivering 10,683 shares
@ $2.56, valued at
$27.3k
|
|
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/13/2023 |
SC 13D/A
| Athyrium Opportunities 2020 LP reports a 32.7% stake in Biora Therapeutics, Inc. |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 5.7% stake in Biora Therapeutics, Inc. |
| 02/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/27/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/20/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/12/2023 |
SC 13D/A
| Athyrium Opportunities 2020 LP reports a 27.8% stake in Biora Therapeutics, Inc. |
| 01/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|
|
|